Sangeeta R. Hingorani

Dr. Sangeeta R. Hingorani

Department of Pediatrics and Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
SHSangeeta R. Hingorani
Sangeeta R. Hingorani
Despite overall improvement in the outcomes of hematopoietic-cell transplantation, kidney injury is a frequent complication. The author reviews the causes, diagnosis, and management of renal complications and disorders after hematopoietic-cell transplantation.

1 February 2009 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
SCSiribha Changsirikulchai
Siribha Changsirikulchai
DMDavid Myerson
David Myerson
KGKatherine A. Guthrie
Katherine A. Guthrie
GMGeorge B. McDonald
George B. McDonald
CACharles E. Alpers
Charles E. Alpers
SHSangeeta R. Hingorani
Sangeeta R. Hingorani
Background and objectives: Thrombotic microangiopathy (TMA) is a known complication of hematopoietic cell transplantation (HCT). The etiology and diagnosis of TMA in this patient population is often difficult because thrombocytopenia, microangiopathic hemolytic anemia, and kidney injury occur frequently in HCT recipients, and are the result of a variety of insults. Design, setting, participants & measurements: The authors reviewed renal pathology and clinical data from HCT patients to determine the prevalence of TMA and to identify correlative factors for developing TMA in the kidney. Kidney tissue was evaluated from 314 consecutive autopsies on patients who died after their first HCT (received between 1992 and 1999). Renal pathology was classified into three groups: (1) no renal thrombus (65%), (2) TMA (20%), and (3) isolated thrombosis (15%). Logistic regression models estimated the associations between each histologic category and clinical parameters: donor and recipient gender, patient age, human leukocyte antigen (HLA) matching of the donor and recipient, total body irradiation (TBI), acute graft versus host disease (GVHD), acute kidney injury, medications, and viral infections. Results: In a multivariate analysis, TMA correlated with acute GVHD grades II to IV, followed by female recipient/male donor, TBI > 1200 cGy, and adenovirus infection. Grades II to IV acute GVHD and female gender were associated with isolated renal thrombus. Conclusions: TMA in HCT recipients is associated with acute GVHD grades II to IV, recipient/donor mismatch, TBI > 1200 cGy, and adenovirus infection.

7 February 2007 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
SHSangeeta R. Hingorani
Sangeeta R. Hingorani
KGK A Guthrie
K A Guthrie
GSG Schoch
G Schoch
NWN S Weiss
N S Weiss
GMG B McDonald
G B McDonald

1 July 2006 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SHSangeeta R. Hingorani
Sangeeta R. Hingorani
High-dose myeloablative hematopoietic cell transplantation is becoming an increasingly common treatment modality for a variety of diseases. Patient survival may be limited by substantial treatment-related toxicities, including chronic kidney disease (CKD). Although the majority of CKD after transplantation is idiopathic, thrombotic microangiopathic syndromes and nephrotic syndrome have been described. Epidemiology, pathogenesis, and potential treatment options for the various clinical syndromes that are associated with CKD in hematopoietic cell transplantation patients is reviewed. As the indications for and the numbers of transplants that are performed worldwide increases, so will the burden of CKD. The nephrologists and oncologists will have to work together to identify patients who are at risk for CKD early to prevent its development and progression to end-stage kidney disease.

1 January 2005 in Kidney International
Verified
Journal Article
Closed access
PDF file
SHSangeeta R. Hingorani
Sangeeta R. Hingorani
KGKatherine Guthrie
Katherine Guthrie
ABA.M.I. Batchelder
A.M.I. Batchelder
GSGary Schoch
Gary Schoch
NANada Aboulhosn
Nada Aboulhosn
GMGeorge B. Mcdonald
George B. Mcdonald

1 December 2008 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SHSangeeta R. Hingorani
Sangeeta R. Hingorani
KSKristy Seidel
Kristy Seidel
ALArmando Lindner
Armando Lindner
TATia Aneja
Tia Aneja
GSGary Schoch
Gary Schoch
GMGeorge McDonald
George McDonald
Chronic kidney disease (CKD) is common after hematopoietic cell transplantation (HCT). We prospectively measured the urinary albumin:creatinine ratio (ACR) in 142 patients. Total (intact) monomeric albumin was determined by liquid chromatography of untreated urine samples collected weekly to day 100 after HCT. Albuminuria was defined as ACR (mg/g creatinine) > 30; proteinuria, as ACR >300. Cox and logistic regression analyses evaluated ACR as a risk factor for clinical events. The prevalence of albuminuria was 37% at baseline, 64% at day 100, and 50% at 1 year. Proteinuria occurred in 4% of patients at baseline, in 15% at day 100, and in 4% at 1 year. Characteristics associated with albuminuria include age, sex, donor type, hypertension, and sinusoidal obstruction syndrome (SOS). Albuminuria was associated with an increased risk of acute graft-versus-host disease (aGVHD) and bacteremia, but not acute kidney injury (AKI). Albuminuria at day 100 was associated with CKD at 1 year (odds ratio = 4.0; 95% confidence interval [CI] = 1.1 to 14.6). Nonrelapse mortality (NRM) risk was elevated (hazard ratio = 6.8; 95% CI = 1.1 to 41.5) in patients with overt proteinuria at day 100. Albuminuria occurs frequently after HCT and is correlated with aGVHD, bacteremia, hypertension, and progression of renal disease. Proteinuria at day 100 is associated with an 6-fold increased risk of NRM by 1 year after HCT.